| Ytd | -54.44% | |
| 1y | -62.15% |
| Open | 12.35 | Prev Close | 12.35 | Low | 12.35 | High | 12.76 | Mkt Cap | 558.30M |
| Vol | 9.93K | Avg Vol | 33.41K | EPS | 0.15 | P/E | 84.80 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 3.70 | Inst. Own | 4.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-28 | 50-d Avg | 24.24 | 200-d Avg | 26.89 | 1yr Est | 0.00 |
Health care sector's oversold stocks present buying opportunity; RSI below 30 signals oversold,
Anbio Biotechnology reported strong 2025 results with sales of $8.65M. The company is diversifying a
Trump's second term is fueling an IPO comeback, with 2025 listings up 50% and five stocks alread